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RESEARCH ARTICLE Open Access
Recombinant interleukin-21 plus sorafenib for
metastatic renal cell carcinoma: a phase 1/2 study
Shailender Bhatia1,13*, Brendan Curti2, Marc S Ernstoff3, Michael Gordon4, Elisabeth I Heath5, Wilson H Miller Jr6,
Igor Puzanov7, David I Quinn8, Thomas W Flaig9, Peter VanVeldhuizen10, Kelly Byrnes-Blake12, Jeremy A Freeman12,
Rachel Bittner11, Naomi Hunder12, Sonia Souza12 and John A Thompson1
Abstract
Background: Despite the positive impact of targeted therapies on metastatic renal cell carcinoma (mRCC), durable
responses are infrequent and an unmet need exists for novel therapies with distinct mechanisms of action. We
investigated the combination of recombinant Interleukin 21 (IL-21), a cytokine with unique immunostimulatory
properties, plus sorafenib, a VEGFR tyrosine kinase inhibitor.
Methods: In this phase 1/2 study, 52 mRCC patients received outpatient treatment with oral sorafenib 400 mg
twice daily plus intravenous IL-21 (10–50 mcg/kg) on days 1–5 and 15–19 of each 7-week treatment course. The
safety, antitumor activity, pharmacokinetic and pharmacodynamic effects of the combination were evaluated.
Results: In phase 1 (n = 19), the maximum tolerated dose for IL-21 with the standard dose of sorafenib was determined
to be 30 mcg/kg/day; grade 3 skin rash was the only dose-limiting toxicity. In phase 2, 33 previously-treated patients
tolerated the combination therapy well with appropriate dose reductions; toxicities were mostly grade 1 or 2. The
objective response rate was 21% and disease control rate was 82%. Two patients have durable responses that are
ongoing, despite cessation of both IL-21 and sorafenib, at 41+ and 30+ months, respectively. The median
progression-free survival in phase 2 was 5.6 months. The pharmacokinetic and pharmacodynamic properties
of IL-21 appeared to be preserved in the presence of sorafenib.
Conclusion: IL-21 plus sorafenib has antitumor activity and acceptable safety in previously treated mRCC patients.
IL-21 may represent a suitable immunotherapy in further exploration of combination strategies in mRCC.
Trial registration: ClinicalTrials.gov Identifier: NCT00389285
Keywords: Interleukin-21, Sorafenib, Renal cell carcinoma (RCC), Immunotherapy, Cytokine, VEGF, Tyrosine kinase
inhibitors (TKI), Durable response, Targeted therapy
Background
The advent of antiangiogenic therapies targeting the
vascular endothelial growth factor (VEGF) pathway has
changed the therapeutic landscape of mRCC [1-7]. How-
ever, the effectiveness of targeted agents appears to
decrease beyond the first-line setting and complete
remission (CR) remains rare. High-dose interleukin-2
(IL-2) has been associated with durable CR in a small
subset of patients, but the therapeutic application of
IL-2 is limited by treatment-associated toxicities and a lack
of biomarkers predictive of responses to therapy [8]. Novel
therapies with distinct mechanisms of action are needed
to further advance patient-outcomes in mRCC.
Interleukin 21 (IL-21) is a class I cytokine produced by
activated CD4+ T cells and natural killer T (NKT) cells
[9]. IL-21 boosts antitumor immunity through modulation
of adaptive as well as innate immune responses. Specific-
ally, IL-21 stimulates expansion and cytotoxicity of CD8+
T cells [10], enhances T-cell dependent B-cell proliferation
and antibody production [9], and facilitates differentiation
and activation of NK cells [9,11]. Unlike interleukin-2
(IL-2), IL-21 renders CD4+ T cells resistant to regulatory
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T cell suppression and does not enhance proliferation of
regulatory T cells [12,13]. IL-21 may also enhance antitu-
mor memory T cell responses [14], and has been associated
with angiostatic activity [15]. Antitumor effects of IL-21
have been observed in various murine cancer models
and may be mediated by cellular and humoral immune
responses [10,16-20].
Recombinant IL-21 therapy has been investigated in
several human trials [21-23]. In a phase 1 trial [22], IL-
21 monotherapy was administered daily in an outpatient
setting to forty-three patients with melanoma (n = 24) or
mRCC (n = 19) on days 1–5 (week 1) and 15–19 (week 3)
of a 7-week treatment course. The maximum tolerated
dose (MTD) of IL-21 monotherapy with this schedule was
determined to be 30 mcg/kg. The most common adverse
events included flu-like symptoms, pruritis and rash.
Treatment was associated with dose-dependent increases
in soluble CD25 (sCD25; IL-2R-α), which is cleaved from
T and NK cells on activation [24]. The antitumor activity in
17 evaluable mRCC patients was promising with an object-
ive response rate (ORR) of 21% (4/17), and a disease con-
trol rate (DCR) of 89%; the four patients with an objective
response had either not received any prior systemic therapy
(n = 2) or had been treated with cytokines (n = 2) [22].
The unique immunostimulatory properties, tolerability
and antitumor activity of IL-21 in mRCC encouraged
investigation of its use in combination with other emer-
ging therapies for mRCC. At the time of conception of
this trial, sunitinib and sorafenib, both VEGF-receptor
tyrosine kinase inhibitors (VEGFR-TKI), had recently been
approved by the United States (US) Food and Drug
Administration (FDA) for treatment of mRCC. The dis-
tinct antitumor mechanisms of action of VEGFR-TKI and
cytokines suggested potential increased efficacy with their
use in combination compared to either agent alone [25].
Indeed, VEGFR-TKI’s have been associated with reversal
of immune suppression in the tumor microenvironment
through reduction of regulatory T-cells and myeloid-
derived suppressor cells and this may enhance the efficacy
of immunotherapeutic agents [26-28]. Similarly, im-
munomodulatory cytokines including IL-21 have been
associated with antiangiogenic effects that may add to
the efficacy of VEGFR-TKIs in mRCC [15]. Preclinical
studies suggested that sorafenib, a VEGFR-TKI, does
not inhibit the effects of IL-21 on CD4+ or CD8+ T cell
proliferation, NK cell activation, or antibody-dependent
cellular cytotoxicity; also, the IL-21 and sorafenib combin-
ation led to improved tumor shrinkage and survival time
as compared to either therapy alone in the murine RenCa
model [29].
This phase 1/2 clinical trial evaluated the safety, anti-
tumor activity, pharmacokinetic and pharmacodynamic
effects of the combination of IL-21 with sorafenib in
patients with mRCC.
Results
Patients
Fifty-two mRCC patients were enrolled and treated in
this study. The baseline characteristics of patients are
shown in Table 1. Demographic characteristics of the
study population were representative of RCC, with a
median age >60 years and male preponderance [30].
The study patients were categorized as either low- or
intermediate-risk by the Memorial Sloan Kettering Cancer
Center (MSKCC) risk classification [31].
Nineteen patients were treated in the phase 1 portion;
approximately half of the patients had received prior
systemic treatment. Thirty-three patients were enrolled
in the phase 2 portion; all patients had received 1 or 2 prior
systemic therapy regimens that included VEGF-receptor
TKIs (VEGFR-TKIs), mammalian target of rapamycin
(mTOR) inhibitors, bevacizumab and/or immunomod-
ulatory therapies; each regimen could consist of a com-
bination of multiple agents.
Safety experience
Phase 1 (dose escalation)
Four dose levels of IL-21 were evaluated in combination
with the standard dose of sorafenib: 10 mcg/kg (n = 8),
30 mcg/kg (n = 4), 50 mcg/kg (n = 4), and 40 mcg/kg
(n = 3). Three patients who received, in violation of the
protocol, either incorrect (n = 2) or insufficient (n = 1)
dosing to allow adequate safety assessment at the planned
doses were replaced by other evaluable patients. One
patient in the 10 mcg/kg cohort experienced grade 3
skin rash; the cohort was expanded with no further
DLTs. No DLT occurred in the 30 mcg/kg cohort. Two
patients in the 50 mcg/kg cohort had grade 3 skin
rashes as DLTs, and the cohort was closed. Although
there were no protocol-defined DLTs at the 40 mcg/kg
dose, all patients in this cohort required sorafenib dose
reductions due to rash or hand-foot syndrome. Hence,
30 mcg/kg was determined to be the recommended
Phase 2 dose of IL-21 in combination with sorafenib at
the standard dose of 400 mg twice daily.
Phase 2
The common clinical and laboratory AEs observed in
phase 2 patients treated with 30 mcg/kg IL-21 plus
sorafenib (starting at 400 mg twice daily) are listed in
Table 2. The majority of toxicities were grade 1 or 2.
The most common clinical symptoms included fatigue,
diarrhea, fever, chills, hand-foot syndrome (HFS), and
skin rash. Many symptoms, including fever, chills, fatigue,
nausea, and vomiting, were observed transiently during
the weeks of IL-21 administration. The most common
grade 3 or higher AEs were skin rash (29%), HFS (24%)
and fatigue (9%). The skin rash was typically a generalized
maculopapular erythematous eruption arising in the first
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two weeks of treatment and progressing rapidly. With
prompt treatment-interruption, the rash typically resolved
over a few days and most patients were able to resume
and tolerate treatment at the reduced dose of sorafenib
while maintaining the same dose of IL-21.
The most common laboratory abnormalities in phase
2 patients included cytopenias, electrolyte abnormalities,
and elevated hepatic transaminases. These were mostly
grade 1 or 2 and were transiently observed during IL-21
treatment weeks. Transient lymphopenia was observed
during the IL-21 administration weeks with rapid recovery
afterwards, a pattern similar to the observations from
IL-21 monotherapy study (Figure 1) [22]. Grade 3 hypo-
phosphatemia, although common, was typically asymp-
tomatic and responded well to oral supplementation.
Adverse effects on renal and hepatic function were
mostly mild and transient, although reversible grade 3
elevations in creatinine and hepatic transaminases occurred
sporadically.
The majority of patients (70%) required a reduction in
the sorafenib dose mostly due to skin rash and HFS. After
reduction in sorafenib dose, most patients tolerated the
combination treatment well without a recurrence of
these toxicities. The IL-21 dose was reduced in 3 patients
due to myalgias, pancreatitis, and rash, respectively. No
treatment-related deaths were observed in this study.
Pharmacokinetics, pharmacodynamics and immunogenicity
Exposure parameters for IL-21 increased with dose and
did not appear to change significantly with repeat dosing.
The mean overall exposure based on AUC0-t after a single
and repeated doses of 30 mcg/kg IL-21 in combination
Table 1 Demographics and baseline characteristics (Phase 1 and 2)
Parameter, n (%) Category/statistic Phase 1 (N = 19) Phase 2 (30 mcg/kg; N = 33)
Gender, n (%) Male 15 (79) 26 (79)
Female 4 (21) 7 (21)
Age in years, Median (range) 63 (48–77) 61 (46–75)
ECOG, n (%) 0 15 (79) 15 (45)
1 4 (21) 18 (55)
Prognostic risk category*, n (%) Low risk 12 (63) 17 (52)
Intermediate risk 7 (37) 16 (48)
Prior systemic treatment regimens for mRCC**, n (%) 0 10 (53) -
1 8 (42) 25 (76)
2 0 (0) 8 (24)
3 1 (5)
Agents used for prior systemic therapy**, n (%) VEGFR-TKIs
Sunitinib 4 (21) 19 (58)
Pazopanib 1 (3)
Cediranib 1 (3)
mTOR Inhibitors
Temsirolimus 5 (15)
Everolimus 2 (6)
Bevacizumab 3 (9)
Immunotherapy
IL-2 4 (21) 11 (33)
Interferon 1 (3)
Vaccine 3 (9)
TLR-9 agonist 1 (5)
IL-2 gene therapy 1 (5)
Other
Vinblastine 1 (3)
ABT-510 1 (5)
*Based on Memorial Sloan Kettering Cancer Center (MSKCC) risk categorization.
**Number of prior treatment regimens, could consist of a combination of agents.
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with sorafenib was 188 (34% CV) and 226 (37% CV)
h*ng/mL respectively. The corresponding mean half-life
estimates were 1.82 (23% CV) and 1.95 (13% CV)
hours. These PK parameter estimates are similar to those
observed with IL-21 monotherapy [22]. As IL-21 PK did
not change with time, the addition of oral doses of sorafe-
nib does not appear to affect the PK of IL-21. Single dose
sorafenib exposure parameters (Cmax, AUC) in the pres-
ence of IL-21 appear comparable to reported values for
single-agent sorafenib (data not shown) [32]. The effect of
IL-21 on sorafenib repeat-dose PK could not be deter-
mined due to the frequency of sorafenib dose reductions.
Soluble CD25 (sCD25; α-subunit of the IL-2 receptor)
is cleaved from T and NK cells on activation [24]. While
this study did not specifically assess cytotoxic function
of CD8 T- or NK- cells (previously evaluated in other IL-21
trials [21,33]), the serum levels of sCD25 were measured at
multiple time points to broadly assess T- and NK- cells
immune activation from IL-21, as described previously
[21,22]. The serum concentration of sCD25 increased
in all dose cohorts following IL-21 dosing. In addition,
sCD25 induction following dosing with 30 mcg/kg IL-21 in
combination with sorafenib was consistent with previous
observations with IL-21 monotherapy (Figure 1), suggest-
ing that sorafenib does not interfere with the pharma-
cological effects of IL-21 [21,22].
Neutralizing anti–IL-21 antibodies were detected in 3
patients. Two of these 3 patients developed infusion reac-
tions characterized as transient flushing, chills, and mild
hypotension; both patients continued to receive IL-21
Table 2 Common adverse events* and laboratory abnormalities in phase 2 patients treated with IL-21 (30 mcg/kg) plus
sorafenib (starting at 400 mg twice daily)
Adverse event preferred term* [N = 33 unless noted] Any grade n (%) Grade 3 n (%) Grade 4 n (%)
Rash† 31 (94) 9 (29) —
Fatigue 23 (70) 2 (6) 1 (3)
Diarrhea 20 (61) 2 (6) —
Pyrexia 20 (61) — —
Chills 18 (55) — —
Palmar-plantar erythrodysaesthesia (hand-foot syndrome) 18 (55) 8 (24) —
Alopecia 15 (45) — —
Vomiting 14 (42) 2 (6)
Influenza-like illness 13 (39) — —
Headache 12 (36) — —
Nausea 12 (36) 2 (6)
Pruritus 12 (36) — —
Arthralgia 10 (30) — —
Pain in extremity 10 (30) 1 (3) —
Laboratory abnormality§ Any grade Grade 3 n (%) Grade 4 n (%)
Lymphopenia 32 (97) 16 (48) 7 (21)
Hypophosphatemia 27 (82) 17 (52) 2 (6)
Lipase high (n = 31) 16 (52) 7 (23) 1 (3)
Hyponatremia (n = 22) 22 (100) 5 (23) —
Platelets low 27 (82) 6 (18) 1 (3)
Hyperuricemia (n = 32) 16 (50) — 7 (22)
Platelets low 27 (82) 6 (18) 1 (3)
AST high 22 (67) 6 (18) —
ALT high 22 (67) 5 (15) —
Leukocytes low 20 (61) 4 (12) —
Neutrophils low 18 (55) 1 (3) 3 (9)
Hypokalemia (n = 9) 9 (100) 1 (11) —
*Adverse events occurring in at least 30% of patients treated are included here.
†Includes any rash preferred term.
§Laboratory abnormalities occurring in at least 50% of patients treated are included. Those occurring in <50% of patients included predominantly grade 1 or 2
electrolyte changes of no significant clinical consequence.
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after pre-medication with antihistaminics and acetamino-
phen. While the effect of these antibodies on IL-21 PK
was not analyzed, the development of these antibodies did
not appear to affect clinical responses; one patient devel-
oped a PR after seroconversion, another patient continued
with SD after seroconversion, and the third patient had
PD during the same cycle as seroconversion. The clinical
significance of the anti–IL-21 antibodies, which were
noted in the phase 1 monotherapy trial as well, remains
unclear [22].
Antitumor effect
Antitumor activity was observed at all dose levels of IL-
21 in combination with sorafenib, with the majority of
patients experiencing shrinkage of the target tumor lesions
per RECIST (Figure 2). Thirteen phase 1 patients com-
pleted at least 1 full treatment course and were evaluable
for response assessment; 3 of these 13 patients (23%) had
a PR and 9 of 13 patients (69%) had SD by independent
radiologic review (Figure 2). In the phase 2 portion of the
study, 7 of the 33 patients (21%) [95% CI: 9, 38.9] had a
confirmed PR and 20 of 33 patients (61%) [95% CI: 42.1,
77.1] had SD by independent review; DCR was 82% [95%
CI: 64.5, 93] (Table 3, Figure 2). The characteristics of
responding patients are shown in Table 4; responses were
seen regardless of the site of disease or the type of prior
therapy. The majority of responders had received prior
targeted therapies including VEGFR-TKIs and/or mTOR
Figure 1 Pharmacodynamic effects of IL-21 at the 30 mcg/kg dose, as monotherapy (previous study [22]) versus in combination with
sorafenib (current study). (A) Induction of serum sCD25, (B) Changes in peripheral blood absolute lymphocyte count (ALC).
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inhibitors. Median PFS was 5.6 months. Two patients had
durable partial responses (near CRs with persistent small
residual masses) that were ongoing at 41+ months and 30+
months after treatment initiation; there had been no growth
in the small residual masses several months after cessation
of both IL-21 and sorafenib.
Baseline characteristics were evaluated to identify
factors predictive of positive IL-21 response. Baseline
VEGF levels have been suggested to predict anti-tumor
response to high-dose IL-2 and to VEGFR-targeted
therapies [34,35]. In this study, no significant associ-
ation between baseline VEGF levels and clinical effi-
cacy endpoints (ORR or PFS) was observed (Additional
file 1: Table S1). In addition, neither baseline sCD25
nor IL-21-mediated sCD25 induction were found to
correlate significantly with clinical efficacy (Additional
file 1: Table S2A and S2B, respectively).
Discussion
This phase 1/2 trial defines the MTD, safety and activity
of an outpatient treatment regimen that includes IL-21,
a cytokine with unique immunostimulatory properties,
in combination with sorafenib, a VEGFR-TKI, in patients
with mRCC. The combination of IL-21 at 30 mcg/kg and
sorafenib appears to be safe with appropriate dose reduc-
tions in sorafenib and to have antitumor activity in mRCC
patients who have failed prior targeted and/or cytokine
therapies.
The optimal dose of IL-21 in combination with the
standard dose of sorafenib (starting at 400 mg twice daily)
was identified as 30 mcg/kg/day. In general, AEs observed
in this study were consistent with toxicities associated
with either agent alone. The most common toxicities
included constitutional, dermatologic and gastrointestinal
symptoms. Dermatologic toxicity was the predominant
reason for sorafenib dose modifications. Grade 3 skin rash
was the DLT in phase 1 patients. Rash was also observed
in 94% (grade 3 in 29%) of phase 2 patients, a higher
proportion than expected with either drug administered
alone [2,22,36]. Similarly, HFS was observed in 55% of
phase 2 patients; the proportion of grade 3 HFS (24%) was
higher than that observed with sorafenib monotherapy
[2,36]. The rate of sorafenib dose-reductions in this study
(70%) is somewhat higher as compared to sorafenib
monotherapy trials (13–52%) [2,36,37]. Reassuringly,
Figure 2 Maximum tumor reduction (per Independent radiologic review) in study patients receiving IL-21 (10-50 mcg/kg) plus
sorafenib (starting at 400 mg twice daily). The maximum percent change from baseline in the sum of the longest diameters of target lesions
per RECIST v1.0 is depicted for the study patients. (NOTE: Two patients from phase 2 are not included due to clinical progressive disease in one
patient and withdrawal from the study due to an AE prior to the restaging evaluation in another patient).
Table 3 Best overall response (per RECIST) for patients
treated in Phase 2 with IL-21 (30 mcg/kg) plus sorafenib
(starting at 400 mg twice daily)
RECIST response Investigator
assessment (N = 33)
Independent
review (N = 33)
Complete response 0 0
Partial response 6 (18%) 7 (21%)
Stable disease 22 (67%) 20 (61%)
Progressive disease 4 (12%) 4 (12%)
Unavailable* 1 (3%) 2 (6%)
*Includes 1 subject who discontinued for toxicity prior to disease reassessment
by both investigator and independent review and 1 subject with progressive
disease on imaging not sent for independent review. All objective responses
were confirmed on a subsequent imaging study.
Bhatia et al. Journal for ImmunoTherapy of Cancer 2014, 2:2 Page 6 of 11
http://www.immunotherapyofcancer.org/content/2/1/2
most patients who required dose-reductions in sorafenib
in our trial tolerated the combination treatment well at
reduced doses of sorafenib (usually 400 mg/day) with-
out recurrence of severe toxicity. Also, there were no
unexpected cumulative toxicities with administration of
repeat courses of IL-21 plus sorafenib. Our study supports
the feasibility of cytokine therapy using IL-21 in patients
previously treated with VEGFR-TKIs, while there have
been safety concerns about using other cytokines such
as HD IL-2 in such patients [38].
While interpreting the efficacy results from this non-
randomized phase 1/2 study, it is important to keep in
mind the limitations of small sample size and selection
bias in phase 2 trials. Similarly, caution should be exercised
in any comparison across trials due to differences in sample
size, patient population and study methods. The clinical
activity of targeted agents in mRCC is consistently lower
in second, or subsequent lines of therapy compared to
first-line therapy suggesting an unmet need for this popu-
lation. Everolimus, the FDA-approved agent for patients
who have failed VEGFR-TKIs, was associated with an
ORR of 1% and a median PFS of 4 months [5]. The
current study’s ORR of 21% (including two patients with
durable responses) and the median PFS of 5.6 months are
encouraging in this pretreated (mostly with agents target-
ing the VEGF pathway) patient population. The antitumor
activity of this combination compares favorably to the
historical activity of sorafenib monotherapy. In a phase
3 study of sorafenib in pretreated (mostly with cytokines)
mRCC patients, the ORR was low (2% by independent
radiologic review) with no CRs [2]. Similarly, in various
studies of sorafenib in patients who had previously re-
ceived VEGF-targeted therapies, response rates have been
low (0%–9.6%) with a modest median PFS or time-to-
progression (around 4 months) [37,39-43]. Although it is
not possible to discern the relative contributions of IL-21
and sorafenib to the overall antitumor activity in this
single-arm study, it is plausible that IL-21 contributed to
the activity of the combination, given the modest ORR
and PFS generally seen with sorafenib monotherapy in
mRCC patients who have previously been treated (espe-
cially with VEGF-targeted therapies). Also, while the ORR
in this trial appears similar to that seen with the IL-21
monotherapy trial, the small sample sizes and the differ-
ences in patient population in the two studies preclude a
direct comparison. The majority of the patients with an
objective response in our trial had previously received
targeted therapies, while most patients in the phase 1
IL-21 monotherapy study were either treatment-naïve
or previously treated with cytokines. The durability of
(near-complete) responses in two patients that persisted
despite cessation of therapy highlight the potential of cyto-
kine immunotherapy to significantly advance outcomes
in a subset of mRCC patients. However, the infrequent
occurrence of durable responses, the desired outcome,
also underscores the importance of identifying predictive
biomarkers in future trials.
Previous efforts to combine immunotherapy with VE
GFR-TKI in patients with RCC have yielded conflicting
results. The results of our trial are in contrast to another
trial that tested the combination of IL-21 with sunitinib,
also a VEGFR-TKI [44]. That trial was discontinued after
the observation of severe hematologic DLTs at the IL-21
dose of 10 mcg/kg in combination with standard dose of
sunitinib. However, sunitinib has proven to be a challen-
ging drug to combine with cytokines or other therapies
due to its toxicity profile [45,46]. Other VEGFR-TKIs
may be better suited for combination with cytokines.
Two studies investigated the combination of sorafenib
with standard-dose IFN in previously untreated patients
with good performance status; although efficacy results
were encouraging, the majority (65–79%) of patients
required IFN dose-reductions with a high treatment-
discontinuation rate (25%) due to toxicities [47,48]. An-
other study compared sorafenib plus low-dose IFN
combination with sorafenib monotherapy and found no
difference in efficacy between the two arms, although
there was less toxicity in the combination arm than that ob-
served in the above-mentioned trials using standard-dose
IFN [49]. In our study, the MTD of IL-21 in combination
with sorafenib is the same as the monotherapy dose of
IL-21; further, IL-21 dose-reductions were uncommon,
allowing for full immunotherapeutic effects of the agent.
Lymphocyte activation by IL-21, as determined by sCD25
Table 4 Characteristics of Phase 2 patients who had objective responses after treatment with IL-21 plus sorafenib
Subject Best response (Independent assessment) Site(s) of disease Prior therapy(ies)
1021 PR Liver, LNs Sunitinib, Temsirolimus
1027 PR Lung, LNs, pancreas, bone Pazopanib
2036 PR Kidney, adrenal, lungs Temsirolimus
2041 PR Liver, tongue Cediranib
2042 PR Liver, lung Sunitinib
2045 PR LNs, liver High-dose IL-2
2046 PR Pancreas, lung, LNs, bone, peritoneum Temsirolimus
Abbreviations: IL-2, interleukin-2; PR, partial response; LNs, lymph nodes.
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levels, appears to be retained in the presence of sorafenib.
Hence, IL-21 may represent a suitable immunotherapy for
further exploration of combination strategies in mRCC,
especially with the emerging more selective VEGFR-TKIs
(such as axitinib) and with other approaches designed to
stimulate the immune system. Trials investigating the
combination of IL-21 with other immunotherapy agents,
such as ipilimumab and anti-PD-1 antibody, in patients
with solid tumors including mRCC are also ongoing
(www.clinicaltrials.gov; NCT01489059 and NCT01629758
respectively).
Some preclinical studies have associated sorafenib, but
not sunitinib, with relative impairment of the NK-cell
effector function [50] and of the dendritic cells and
adaptive immune responses [51]. However, the clinical
significance of these preclinical findings has been unclear.
Sorafenib therapy has not been associated with increased
risk of infections, which would have supported a drug’s
immunosuppressive potential, in the major clinical trials
[2]. In the preclinical study of IL-21 plus sorafenib in the
murine RenCa model, sorafenib did not inhibit the effects
of IL-21 on CD4+ or CD8+ T cell proliferation, NK cell
activation, or antibody-dependent cellular cytotoxicity,
and led to improved tumor shrinkage and survival time as
compared to either therapy alone [29]. Similarly, the com-
bination of sorafenib with Interleukin-2 in murine studies
did not show any significant inhibitory effects of sorafenib
on IL-2 induced NK-cell expansion [25]. While the paucity
of well-defined RCC antigens/biomarkers limits our ability
to rigorously assess the effects of sorafenib on IL-21 in-
duced tumor specific immune responses in this study, the
data on sCD25 levels and the lymphocyte counts suggest
that sorafenib did not interfere with the pharmacological
effects of IL-21.
Conclusions
Combination therapy with IL-21 and sorafenib has anti-
tumor activity with acceptable safety in previously treated
mRCC patients. Given its unique immunostimulatory
properties, antitumor activity, and tolerability in an out-
patient regimen, IL-21 may also be suitable for combin-
ation with other antiangiogenic and immunomodulatory
therapies. Such combinations may increase the efficacy of
existing therapies and lead to improved patient outcomes.
Methods
Study treatment and design
This was a phase 1/2, open-label, multicenter study of
IL-21 given in combination with sorafenib to patients
with mRCC. Sorafenib was administered at the US FDA-
approved dosing schedule of 400 mg orally twice daily
starting on day 1 with dose modifications allowed per the
package insert. Recombinant IL-21 [ZymoGenetics (now
Bristol-Myers Squibb), Seattle, WA] was administered
by rapid intravenous (IV) injection daily on days 1–5
(week 1) and 15–19 (week 3) of a 7-week treatment
course, in an outpatient treatment setting. Restaging
radiologic evaluations were performed during the seventh
week of each treatment course. Patients with stable disease
(SD) or better were eligible for retreatment with additional
courses of IL-21 plus sorafenib.
In the phase 1 portion, a 3 + 3 dose-escalation design
was used to estimate the maximum tolerated dose (MTD)
of IL-21 in combination with the standard dose of sorafe-
nib. Four dose levels of IL-21 (10, 30, 40 and 50 mcg/kg)
were tested in cohorts of up to 6 evaluable patients per
dose, starting at the 10 mcg/kg dose level. Even though
the MTD of IL-21 monotherapy was 30 mcg/kg in the
phase 1 monotherapy trial, the only patient treated with
50 mcg/day dose in that trial had transient grade 3 neutro-
penia that did not recur with re-treatment [22]. Hence,
two dose levels of IL-21 above 30 mcg/kg were included
in the current study.
The phase 2 portion of the study further evaluated the
safety and antitumor activity of IL-21 administered at the
MTD in combination with sorafenib in mRCC patients
receiving second- or third-line treatment.
Patients
Eligibility requirements included mRCC of predominantly
clear-cell histology; age ≥ 18 years; measurable disease per
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.0 [52]; life expectancy > 6 months; Eastern
Cooperative Oncology Group (ECOG) performance status
0 or 1; prior nephrectomy; no brain metastases; no uncon-
trolled hypertension; and adequate renal, hepatic and
hematologic function. Prior systemic therapy for mRCC
was required for phase 2 patients, but no more than 2
prior systemic therapeutic regimens were allowed; prior
IL-21 or sorafenib administration was not allowed. Institu-
tional review boards of participating centers approved
the protocol, and patients gave written informed consent
before study-specific procedures began.
Safety and efficacy assessments
Toxicities were evaluated using National Cancer Insti-
tute’s Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0. Dose-limiting toxicity (DLT) was
designated during treatment course 1 and was defined as
any treatment-related clinical adverse event (AE) ≥ grade 3
(except fatigue, fever or transient rigors, nausea or vomiting
without antiemetic therapy) or any treatment-related grade
4 (or grade 3 lasting >3 days) laboratory abnormalities
(except lymphopenia, leukopenia, transient neutropenia
not associated with infection, asymptomatic electrolyte
abnormalities and asymptomatic elevations in amylase/
lipase). Safety endpoints included incidence and severity
of adverse events and clinical laboratory abnormalities.
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For antitumor activity assessment, results from restaging
radiologic evaluations were categorized per RECIST ver-
sion 1.0 as CR, partial response (PR), SD or progressive
disease (PD) [52]. Both investigator and independent
radiology review were conducted for all patients. Efficacy
endpoints included ORR (defined as the rate of PR + CR
at the time of best response), disease control rate (defined
as the rate of SD + PR + CR at the time of best response)
and progression free survival (PFS).
Pharmacokinetics, pharmacodynamics and immunogenicity
Serum and plasma samples were collected at select time
points for evaluation of IL-21 and sorafenib pharmacokinet-
ics (PK), respectively. IL-21 concentration was determined
using a validated ELISA (ZymoGenetics, Seattle, WA); the
lower limit of quantification of this assay was 0.112 ng/mL.
Sorafenib concentration was determined utilizing liquid
chromatography with the tandem mass spectrometric de-
tection method (Covance Bioanalytical Services, IN). Cmax
(maximum observed concentration), AUC0-t (area under
the concentration versus time curve from time zero to the
last measurable timepoint), and t1/2,λz (terminal half-life)
were estimated using WinNonlin Professional v5.2.1 soft-
ware. Due to the sparse sampling scheme, reported t1/2,λz
values should be interpreted with caution.
Serum samples to determine soluble CD25 (sCD25) con-
centration using a validated enzyme-linked immuno-
sorbent assay (ELISA) (ZymoGenetics, Seattle, WA) were
drawn at select time points during course 1. Baseline
serum and plasma VEGF levels were determined using
a validated immunoassay (Quest Inc., Valencia, CA). The
relationships of baseline VEGF and sCD25 levels and that
of change in sCD25 levels to clinical efficacy endpoints
(ORR and PFS) were explored.
Serum specimens were collected at select time points to
screen for IL-21 binding antibodies using ELISA (Zymo-
Genetics, Seattle, WA); samples containing IL-21 specific
antibodies were evaluated for neutralizing activity by a
cell-based bioassay.
Statistical analysis
Based on the binomial distribution, it was determined
that a sample size of 30 subjects in the phase 2 portion
of the study would provide approximately 95% probability
of observing a relevant safety event in one or more subjects
if the true population incidence rate was 10% or greater.
Given the early phase of this study, formal assessments of
power for efficacy endpoints were not conducted.
Kaplan-Meier estimates for median PFS were computed
with the earliest assessment of progression (by investigator
or independent review) treated as time of progression.
SAS version 9.1 was used to perform all analyses.
The association between baseline levels of VEGF and
sCD25, as well as sCD25 induction, with outcomes of
clinical efficacy was explored using a series of Cox
regression (PFS) and logistic regression (ORR) models
(both raw and log-transformed values of each biomarker
were analyzed).
Results from this study have been presented in part at
the following conferences
AACR 2007 – poster (Bhatia)
EORTC 2008 – poster (Flaig)
iSBTc 2008 – presentation (Bhatia)
ASCO 2009 – poster (Bhatia)
Additional file
Additional file 1: Table S1. Baseline serum VEGF levels, overall and by
ORR categories. There does not appear to be any trend in mean or
median VEGF by RECIST responses observed in the non-transformed
serum VEGF values. Similar results were seen for the log-transformed
serum VEGF values (data not shown). Table S2A Baseline serum sCD25
levels, overall and by ORR categories. There does not appear to be any
trend in mean or median sCD25 by RECIST responses observed in the
non-transformed serum sCD25 values. Similar results were seen for the
log-transformed serum sCD25 values (data not shown). Table S2B
Change from Baseline serum sCD25 levels, overall and by ORR categories.
There does not appear to be any trend in mean or median Change from
Baseline serum sCD25 levels by RECIST responses observed in the
non-transformed serum sCD25 values. Similar results were seen for the
log-transformed serum sCD25 values (data not shown).
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